3.41
+0.05(+1.49%)
Currency In USD
Address
650 Chapel Street
South Yarra, VIC 3141
Australia
Phone
61 3 9826 0399
Website
Sector
Healthcare
Industry
Biotechnology
Employees
33
First IPO Date
October 16, 2020
| Name | Title | Pay | Year Born |
| Dr. Frederic Guerard M.S., Pharm.D. | Chief Executive Officer | 775,570 | 1973 |
| Ms. Karen Adams CPA | Vice President of Finance & Company Secretary | 304,370 | 1972 |
| Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. | Founder & Chief Innovation Officer | 602,175 | 1975 |
| Dr. Julie Clark M.D., M.S. | Senior Vice President of Clinical Development | 0 | 1976 |
| Mr. Thomas Charles Reilly | Chief Financial Officer | 0 | 1972 |
| Dr. Arshad M. Khanani M.A., M.D. | Chief Medical Advisor & Chairman of Medical Advisory Board | 0 | 1979 |
| Mr. Anand Sundaram | Vice President Marketing | 0 | N/A |
| Mr. Kevin Bitter | Vice President of Strategy & Corporate Development | 0 | 1992 |
| Dr. Fang Li Ph.D. | Senior Vice President of Regulatory Affairs | 0 | 1964 |
| Ms. Jen Watts | Vice President Global Clinical Operations | 0 | N/A |
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.